COMP <GO>
ABCL vs INDV // RSI-14 & 200D SMA MOMENTUM
AbCellera Biologics Inc. (NASDAQ) VS. Indivior Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ABCL 2
— INDV 7
▲ RSI-14 & 200D SMA MOMENTUM LEADER: INDV
LAST: $11.12 (-9.37%) • MKT CAP: $3.97B
rsi-technicals
49.0
LAST: $35.37 (+0.34%) • MKT CAP: $4.17B
rsi-technicals
52.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABCL VS. INDV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABCL | INDV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 80.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.50% | 62.20% | -82.70 | INDV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 13.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.11% | -2.24% | -1.87 | INDV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 21.10% | -81.10 | INDV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 16.90% | -76.90 | INDV | /net-margins <GO> |
| Revenue Growth (YoY) | 160.60% | 4.30% | +156.30 | ABCL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.60 | 3.13 | +3.47 | ABCL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 5/9 | -1.00 | INDV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 49.0 | 52.3 | -3.30 | INDV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.97B | $4.17B | -$200.6M | INDV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABCL REV | INDV REV | ABCL GROSS % | INDV GROSS % | ABCL FCF | INDV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $75.1M | $1.24B | — | 80.2% | -$174.1M | -$93.0M |
| FY 2024 | $28.8M | $1.19B | — | 80.6% | -$187.0M | $7.0M |
| FY 2023 | $38.0M | $1.09B | — | — | -$43.9M | -$349.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABCL // BETA —
INDV // BETA 1.15